Voya Investment Management LLC Buys 60,479 Shares of Natera, Inc. $NTRA

Voya Investment Management LLC boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 23.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 313,089 shares of the medical research company’s stock after acquiring an additional 60,479 shares during the quarter. Voya Investment Management LLC’s holdings in Natera were worth $129,403,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in Natera during the second quarter valued at approximately $2,962,770,000. Aberdeen Group plc boosted its holdings in shares of Natera by 26,462.7% in the 3rd quarter. Aberdeen Group plc now owns 1,398,794 shares of the medical research company’s stock worth $578,136,000 after purchasing an additional 1,393,528 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after purchasing an additional 11,793 shares during the period. Maverick Capital Ltd. raised its holdings in Natera by 24.1% during the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after buying an additional 227,605 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Natera by 10.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after buying an additional 80,440 shares during the period. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $363.50 price target on shares of Natera in a research report on Friday, November 6th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. Guggenheim boosted their price objective on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Barclays increased their target price on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, BTIG Research raised their target price on shares of Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a report on Tuesday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $394.31.

Get Our Latest Analysis on NTRA

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 3,419 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $409.77, for a total value of $1,401,003.63. Following the transaction, the insider owned 101,323 shares of the company’s stock, valued at $41,519,125.71. This represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 470 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $391.49, for a total value of $184,000.30. Following the completion of the sale, the chief financial officer owned 45,779 shares in the company, valued at approximately $17,922,020.71. The trade was a 1.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 47,056 shares of company stock valued at $17,760,989 over the last quarter. 5.05% of the stock is currently owned by insiders.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $289.50 on Thursday. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The business has a 50 day simple moving average of $377.35 and a two-hundred day simple moving average of $272.44. The firm has a market capitalization of $41.98 billion, a PE ratio of -253.95 and a beta of 1.55.

Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. The business had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. During the same period in the prior year, the company posted ($0.64) EPS. The company’s quarterly revenue was up 34.1% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.25 EPS for the current fiscal year.

About Natera

(Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

Further Reading

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.